# BPC-157 TB-500 dosage in the research literature (animal models, not guidance) > BPC-157 TB-500 dosage as reported in studies: animal-model doses by body weight, routes studied, half-life, reconstitution, and why no validated blend dose exists. Cited, not prescriptive. Doses are reported as administered to species in published research — never as a protocol. The blend itself has no validated dose, half-life, or cycling schedule. ## BPC-157 TB-500 dosage in the research literature BPC-157 TB-500 dosage has no validated figure for the blend. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial — for example, roughly 10 mg + 10 mg, or a 20 mg combined vial — but no peer-reviewed combination dose-finding study exists [4]. What follows is reported strictly as administered to species in studies, not as human guidance. For the BPC-157 component, rodent studies commonly express dose per body weight, frequently around 10 µg/kg and 10 ng/kg [1]; gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats [2]. For the TB-500 / Thymosin Beta-4 component, the animal range is wide: 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study, with the optimal modeled near 3.75 mg/kg and 18 mg/kg giving no benefit — higher was not better [4]. Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend or the 7-mer: intravenous Tbeta4 was well tolerated in early-phase safety studies [4]. Community "loading then maintenance" blend protocols have no controlled-trial basis. ## Half-life and pharmacokinetics No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend [4]. BPC-157's elimination half-life was reported under 30 minutes in an animal PK study [2]. Human intravenous Thymosin Beta-4 showed dose-proportional PK with half-life increasing at higher doses, but no specific half-life is established for the TB-500 heptapeptide [4]. ### What is the half-life of BPC-157 and TB-500? BPC-157's elimination half-life was reported under 30 minutes in animal PK studies [2]; no validated human half-life exists for either constituent at research-use doses, and none for the blend [4]. The human Tbeta4 PK on record is for the full-length protein, not the marketed fragment. ## Routes studied, including oral and the "Wolverine injection" Several routes appear in the underlying research. Intraperitoneal dominates the rodent efficacy studies for both peptides [1][4]. Intravenous appears in the human Phase 1 work on full-length Tbeta4 and a BPC-157 IV safety pilot [4]. Local, intra-lesional, and topical routes appear in individual-compound wound and tendon models. Subcutaneous and intramuscular are the predominant research-community routes for the blend — but not from controlled human efficacy trials [4]. ### Oral versus injectable routes in the research literature Searches for "BPC 157 TB 500 oral" run into a thin record: BPC-157 is studied as a "stable gastric" peptide, which is why oral routes appear in its literature [2], but blend oral products are marketed without validated pharmacokinetics — the oral behavior of the pairing has not been characterized [4]. Injectable routes (intraperitoneal in the rodent studies; subcutaneous and intramuscular in community use) carry the bulk of the data, and even those are single-compound and largely preclinical. ### Routes used for the Wolverine blend in research settings The predominant research-community routes for the blend are subcutaneous and intramuscular, with intraperitoneal dominating the underlying rodent studies for both peptides [1][4]. None of these routes is supported by a controlled human efficacy trial of the combination. The phrase "wolverine injection" describes a route of administration, not a validated product or dose. ## Reconstitution, mixing, and cycling Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [4]. A frequent practical caveat: product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed, which compounds the existing fragment-versus-full-protein caveat around TB-500 [4]. ### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated [4]. Product identity and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This describes how research material is handled, not a preparation instruction for use. ### Can you mix BPC-157 with TB-500 in the same syringe? Research-community practice reconstitutes the two peptides either separately or in a shared vial [4]. Whether they are co-housed does not change the central fact: there is no controlled study defining a combined dose, ratio, or stability profile for the pairing [4]. Compatibility in a single container is a handling question; the combination's pharmacology remains unstudied. ### How often should you inject BPC-157 and TB-500? There is no validated dosing schedule for the blend [4]. Community "loading then maintenance" protocols have no controlled-trial basis and should not be treated as validated dosing. Frequency claims circulating online are not grounded in the published record. ### How do you cycle BPC-157 and TB-500? There is no validated cycling protocol [4]. Fixed-ratio vials (for example, 10 mg + 10 mg) and "loading" schedules circulating online have no basis in controlled human trials. The non-monotonic Tbeta4 dose-response — where the highest dose gave no benefit — directly undercuts "more is better" loading rationales [4]. ## Why the dose record cannot become guidance Every figure on this page is an artifact of a study design, not a recommendation. The rodent doses are expressed per body weight in animals dosed intraperitoneally in controlled experiments [1]; the wide Tbeta4 range comes from disease models that bear no fixed relationship to a research-use protocol for a fragment blend [4]. Translating any of these numbers into a human regimen would require pharmacokinetic, dose-finding, and safety data that simply do not exist for the pairing. The safety picture reinforces the point. The combination's safety is unproven, and a specific theoretical concern attaches to the TB-500 leg: thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could in principle support tumor progression — a concern that compounds when two pro-repair peptides are combined [4]. A 2026 review of unapproved musculoskeletal peptides notes scarce human safety data and the potential for serious harm across this whole class [9]. The dose record is here to be understood, not followed. --- A pressed-herbarium reading room for the BPC-157 and TB-500 literature — two peptides mounted as specimens and cited to source, with no clinic behind the field-book and nothing here for sale.